TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04469023

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TS-142
Description: Participants received multiple-dose of 2.5, 5, 10 mg of TS-142 or placebo (oral tablet)
Study: NCT03049579

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Weiquan Yogurt with probiotics
Description: 150 ml daily consumption for a total of 12 weeks
Study: NCT00732654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 4mg/day
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 4mg/day
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 4mg/day
Description: Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Study: NCT01404078

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Double dose Polycap
Description: 2 Capsules of low strength polycap with 30mEq of Potassium
Study: NCT04095312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general HBP surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general Uro surgery
Study: NCT00732654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Protein Extract Immunotherapy goal of 7mg/day
Description: Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Powder Immunotherapy goal dose 2000 mg/day
Description: Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
Study: NCT04095312

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Revo-i robotic surgery system (Model MSR-5100)
Description: for evaluating the clinical safety and effectiveness of the automated robotic robot, Revo-i Surgical Robot System (Model MSR-5100), used for general colorectal surgery
Study: NCT03803930

Intervention type: DEVICE
Group type: OTHER
Intervention: Using 22G FNB, the first pass is SP
Description: Using 22G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.

Intervention type: DEVICE
Group type: OTHER
Intervention: Using 22G FNB, the first pass is MWST
Description: Using 22G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.

Intervention type: DEVICE
Group type: OTHER
Intervention: Using 20G FNB, the first pass is SP
Description: Using 20G FNB, the first pass is SP and the pass sequence is SP-MWST-SP-MWST.

Intervention type: DEVICE
Group type: OTHER
Intervention: Using 20G FNB, the first pass is MWST
Description: Using 20G FNB, the first pass is MWST and the pass sequence is MWST-SP-MWST-SP.technique-slow pull.
Study: NCT02757573

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hypercarbia
Description: PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
Study: NCT02383810

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Elsiglutide
Study: NCT00732654

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk Powder Immunotherapy goal dose 1000mg/day
Description: Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
Study: NCT03432208

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: GI consult

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: GI consult
Study: NCT03582839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PROTECT+
Description: The early intervention PROTECT+ consists of a cognitive-behavioral 4-session brief-protocol (100 minutes) and targets empirically identified risk factors of (I)GD/IUD, i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
Study: NCT02940028

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expressive writing
Description: Brief expressive writing intervention

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control writing
Description: Brief fact-based writing exercise.
Study: NCT02602704

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bazedoxifene
Description: Bazedoxifene 20mg/day (Viviant) for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vit D
Description: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium/Vit D
Description: Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 \* 2/day) for 48 weeks
Study: NCT02663115

Intervention type: OTHER
Intervention: Biopsy of the diaphragmatic muscle

Intervention type: OTHER
Intervention: Biopsy of the diaphragmatic muscle

Intervention type: OTHER
Intervention: Skeletal muscle biopsy

Intervention type: OTHER
Intervention: Skeletal muscle biopsy
Study: NCT04537572

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: comparison of sample collection methods
Description: Samples will be collected via finger-stick, saliva collection, and traditional phlebotomy to determine effects on COVID-19 antibody test results.
Study: NCT01759628

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.pylori eradication
Description: The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
Study: NCT03846076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: Cognitive behavioral therapy
Study: NCT02030860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paricalcitol
Description: Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abraxane
Description: Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
Study: NCT00664157

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facial expression recognition of emotion
Description: Facial expression recognition test Lexical decisiontest

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Facial expression recognition of emotion
Description: Facial expression recognition test Lexical decision test
Study: NCT05764811

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Canagliflozin 100mg
Description: 100 mg daily for a month
Study: NCT02912741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vanish xt Extended Contact Varnish
Description: resin modified glass- ionomer cement varnish applied as a thin layer coating and cured

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resin infiltration
Description: low viscous light cure resin applied in layers and cured
Study: NCT00431223

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive remediation therapy
Description: 36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
Study: NCT02668055

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TB4
Description: Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
Study: NCT01899040

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neuromodulation for episodic migraine headache

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: neuromodulation for episodic migraine headache
Study: NCT02253160

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia CMNC
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectra Optia CMNC
Description: The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBE Spectra MNC
Description: It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: COBE Spectra MNC
Description: It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Granulocyte-colony stimulating factor (G-CSF)
Description: Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
Study: NCT05006391

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tele-Coaching (Online) Community-Based Exercise
Description: PHASE 1-Intervention Phase (6 months): Participants will engage in an individual tailored home-based exercise program involving aerobic, resistance, balance and flexibility training \~60min, 3 times per week for 24 weeks. Intervention will include: Component 1) biweekly 60 min personal online coaching with a certified trainer from the YMCA (13 sessions) who will monitor and progress exercise intensity; Component 2) weekly online group-based exercise classes \~60 min each led by a trainer at YMCA; Component 3) monthly online evidence-based self-management education sessions focused on topics related to self-management and health, and physical activity living with HIV; and Component 4) a wireless physical activity monitor (WPAM) to self-monitor steps, distance, calories burned, and active minutes.~PHASE 2: Post-Intervention (6 months): Participants will be encouraged to continue with unsupervised home / outdoor-based exercise 3 times per week and to continue using their WPAM throughout.
Study: NCT02565862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daclatasvir
Study: NCT03801486

Intervention type: OTHER
Intervention: Experimental: Sprouted Chickpea Flour
Description: 255g of pasta with 40% sprouted chickpea flour and 60% semolina flour (SCF40) with butter.

Intervention type: OTHER
Intervention: Control: Semolina Flour
Description: 255g of pasta with 100% semolina flour (SEM100) with butter.
Study: NCT01845493

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Alpha Sprout Homogenate
Description: Alpha Sprout Homogenate

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Sulforaphane Homogenate
Description: Active
Study: NCT02565862

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT03550456

Intervention type: OTHER
Intervention: ECC
Description: Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
Study: NCT00998985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, orally, once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, orally, once a day for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet, orally, once a day for 7 days
Study: NCT04168905

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AOTI Inc. TWO2 topical oxygen therapy equipment
Description: Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: AOTI Inc. TWO2 topical oxygen therapy equipment
Description: Patients will apply themselves oxygen therapy at home for 5 days a week, 90 minutes a day, rest for 2 days, and follow-up once a week. A total of 12 weeks of treatment, or recieving treatment till wound healed.
Study: NCT01700140

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB D-0701
Description: Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SyB D-0701
Description: Study drug patches \[Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch\] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study: NCT03550456

Intervention type: OTHER
Intervention: ECC with CLE
Description: Continuous Laryngoscopy is endoscopy of the larynx used to obtain a view of laryngeal obstruction during exercise.

Intervention type: OTHER
Intervention: Speech therapy
Description: Patients with diagnosis of EILO will be sent to a speech therapist for at least 6 training sessions.
Study: NCT03917914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisoprolol
Description: As in arm description

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: As in arm description
Study: NCT01700140

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
Study: NCT00102804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: 500 milligrams per square meter (mg/m\^2), intravenous (IV) administration, every (q) 21 days, until disease progression

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV administration, q 21 days

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Best Supportive Care
Description: Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
Study: NCT02339441

Intervention type: DRUG
Intervention: Methotrexate
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.

Intervention type: DRUG
Intervention: Mycophenolate mofetil
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.

Intervention type: DRUG
Intervention: Cyclophosphamide
Description: Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
Study: NCT04275492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
Description: Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Praxol hydrochloride sustained release tablet Specification: 0.375mg/ tablet (in pramipexole hydrochloride)
Description: Praxol hydrochloride sustained release tablets, 0.375mg/ tablet, are manufactured by hongguanbio pharmaceutical co., LTD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
Description: Siforl® is produced by Boehringer Ingelheim International Gmbh

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramipexole hydrochloride sustained-release tablet (Siforl®) Specification: 0.26mg/ tablet (in pramipexole)
Description: Siforl® is produced by Boehringer Ingelheim International Gmbh
Study: NCT01638676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
Study: NCT04454749

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Mesurement of E2, P4, LH, FSH hormones

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Mesurement of E2, P4, LH, FSH hormones

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood test
Description: Mesurement of E2, P4, LH, FSH hormones

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Follicular measurement and endometrium measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Follicular measurement and endometrium measurement

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Follicular measurement and endometrium measurement
Study: NCT04929691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP helmet
Description: helmet-based CPAP ventilation for eligible patients; assess the feasibility and acceptability of the helmet-based CPAP ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care non-helmet based CPAP ventilation
Description: Standard of care ventilation without helmet-based CPAP
Study: NCT03463213

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SHE Tribe
Description: Social network-based peer-facilitated intervention to promote adoption of health behavior
Study: NCT00713557

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Intervention type: DEVICE
Intervention: drug-eluting stent
Description: drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent

Intervention type: DRUG
Intervention: Tirofiban
Description: upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
Study: NCT01864486

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intelligent Retinal Implant System